Kate Therapeutics Acquisition, Valuation, Funding & Investors

Philogen SpA is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. The company's focus is predominantly related to oncology drug development, although the company has also brought products for the treatment of chronic inflammatory diseases to the clinic. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others. Geographically, the company operates in the European Union, Switzerland, and the United States of America.

CStone Pharmaceuticals is engaged in developing and commercializing of immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment.

Suzhou Ribo Life Science Co Ltd is a biopharmaceutical company engaged in oligonucleotide research and development, with a focus on siRNA therapeutics. It has one Core Product, RBD4059 (FXI-targeting siRNA), targeting thrombotic diseases, among a pipeline of seven in-house discovered drug assets in clinical trials for seven indications across cardiovascular, metabolic, renal and liver diseases, including four in phase 2 clinical trials.

Letu is a drug research and development manufacturer building a precision medicine ecosystem encompassing biological drugs, intelligent manufacturing, genetic testing, and medical services in China.

Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.

Kissei Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. Pharmaceuticals is the company's reportable segment. The company’s operations span across the globe, while the vast majority of revenue is generated in Japan, followed by Europe. Kissei operates a variety of subsidiaries. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.

Blue Jet Healthcare Ltd is engaged in manufacturing of Pharma Intermediate, APIs used in Pharmaceutical and Healthcare Products. The operations of the company are organized in three product categories which are contrast media intermediates, artificial sweeteners, pharma intermediates, and active pharmaceutical ingredients. Geographically, it operates in Norway, France, India and Rest of the World.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Guilin Sanjin Pharmaceutical Co Ltd is engaged in research and development of proprietary Chinese medicines and natural medicines.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.

Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.

Formation Bio is a South San Francisco-based biotechnology firm accelerating drug development through optimized clinical trials. It partners with pharma companies like Eli Lilly to redesign trial operations, leveraging technology for faster patient recruitment and data management in oncology and rare diseases.

La Renon is an Indian pharmaceutical company manufacturing formulations for cardiology, diabetology, and neurology. Headquartered in Ahmedabad, Gujarat, it produces 300+ products including tablets, injectables, and ophthalmics, exported to 25 countries in Asia and Africa. The firm operates a WHO-GMP certified facility with 200 employees, focusing on chronic disease therapies like antihypertensives and statins.

Antekin Biotech is a vaccine company. Antekin Biotech maintains integrated capabilities across research, development, manufacturing, and commercialization of vaccines.